RAD51B and non-small cell lung carcinoma: Furthermore, after adjustment for some potential confounding factors, the multivariate Cox regression analysis showed that the death risk of patients with high expressions of RAD51B decreased by 26% compared to those with low expression, especially for NSCLC patients with squamous cell carcinoma.